Sign inJoin waitlistJoin the waitlist

Marjorie Zauderer

Program Director · Westchester Medical Center

Credentials: · · · · ·

History

Westchester Medical Center
Present
WMCHealth Cancer Center · Westchester Medical Center
Present
New York Medical College
Present

Memorial Sloan Kettering Cancer Center
2010–2012
Internal Medicine
Columbia University Medical Center
2006–2009
Molecular Biophysics & Biochemistry, Yale University
Columbia Univ Coll of Phys & Surgeons
2002–2006
Molecular Biophysics & Biochemistry, Yale University
1998–2002

Research

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Cell · 2022 · 541 citations
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Cancer Discovery · 2018 · 519 citations
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab
Cancer Discovery · 2021 · 515 citations

PA
Prasad Adusumilli
31 papers
Valerie Rusch
31 papers
MO
Michael Offin
26 papers · 1 as a fellow
ML
Marc Ladanyi
22 papers
Jennifer Sauter
20 papers
AR
Andreas Rimner
19 papers
LK
Lee Krug
16 papers
MK
Mark Kris
14 papers
WT
William Travis
14 papers
MG
Michelle Ginsberg
11 papers
Charles Rudin
10 papers
GN
Garrett Nash
8 papers

Grants

A Phase I/II Combination Immunotherapy Clinical Trial: Mesothelin-Targeted Chimeric Antigen Receptor T Cells and Checkpoint Blockade Agent in Pleural Mesothelioma
National Cancer Institute · R01
PI · $2.9M · Sloan-Kettering Inst Can Research
2019–2025
Therapeutic Efficacy of the CRL Inhibitor MLN4924 in NF2 Mutant Mesothelioma
National Cancer Institute · R01
PI · $2.2M · Columbia University Health Sciences
2016–2021

Clinical trials

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma
Principal investigator · Withdrawn · Phase 1
Memorial Sloan Kettering Cancer Center
2015
Clinical and Histopathologic Characteristics of BAP1 Mutations
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
2013–2020
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Principal investigator · Completed · Phase 2
Sellas Life Sciences Group
2010–2017
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
Site PI · Recruiting · Phase 1, Phase 2
Orion Corporation, Orion Pharma
2023–2027